ARTICLE | Clinical News
SCY-078 regulatory update
March 3, 2014 8:00 AM UTC
Scynexis said FDA granted Qualified Infectious Disease Product (QIDP) designation for oral SCY-078 to treat invasive Candidiasis, including Candidemia and invasive Aspergillosis. In 2H14, Scynexis pla...